Alzheon, a clinical-stage biopharmaceutical company, secures $100million in series E round funding. The round was led by Alerce Medical Technology Partners. The business, which in 2022 successfully collected $50 million in a Series D financing round, plans to use the money to grow both its R&D sector and its operations.
Alzheon is a clinical-stage biopharmaceutical firm headed by Martin Tolar, MD, PhD, Founder, President, and CEO. The company is developing a wide range of therapeutic candidates and diagnostic assays for patients with Alzheimer’s disease and other neurodegenerative illnesses.
It is dedicated to creating novel medications that target the underlying pathophysiology of neurodegeneration. Phase 3 development is underway for ALZ-801/valiltramiprosate, the company’s principal Alzheimer’s clinical candidate. This oral medication has the ability to modulate AD disease progression.
Read also – [Funding News] CA-based Aepnus Technology Secures $8Million in Seed Funding
In preclinical experiments, the oral small drug ALZ-801 has been shown to completely prevent the development of neurotoxic soluble amyloid oligomers. With the goal of advancing patient-focused medicines, its clinical expertise and technological platform are concentrated on creating drug candidates and diagnostic assays through a precision medicine approach based on genetic and biomarker information specific to each individual.
About Alzheon, Inc.
Alzheon, Inc. is dedicated to creating cutting-edge medications by tackling the underlying pathology of debilitating neurodegenerative illnesses head-on. Their top option for treating Alzheimer’s disease, ALZ-801, is an oral small molecule prodrug of tramiprosate that completely prevents the brain from producing harmful soluble amyloid oligomers.
The safety and effectiveness profile of ALZ-801’s active ingredient, tramiprosate, which has been assessed in over 2,000 clinical trials involving Alzheimer’s patients, is further enhanced by this simple-to-take tablet.
